Sponsored by
They reported a huge improvement in median overall survival for recurrent / recalcitrant Anaplastic Astrocytoma. 1,136 days for this experimental treatment compared to 590 days for the standard Temozolomide. That is more than double. This is given by convection enhanced delivery. This drug is a new TGF-Beta antisense drug. It should theoretically work for a wide variety of cancers and is also being studied for use against the COVID-19 virus.